Phase III REGION-I Study Shows PEP005 (ingenol mebutate) Gel 0.05% May Reduce Pre-Cancerous Skin Lesions in Patients with Actinic Keratosis

Specialty pharmaceutical company LEO Pharma announced that findings from a Phase III study evaluating PEP005 (ingenol mebutate) Gel 0.05% to treat actinic keratosis (AK), a common pre-cursor to skin cancer, were presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) (Scientific Session Poster Discussion: P105). Results from REGION-I demonstrated treatment with PEP005 Gel once daily for 2 consecutive days (n=3D117) on non-head locations resulted in significant clearance of AK lesions when compared with the vehicle or placebo (n=3D118). The study showed a 66.7% median reduction in the number of AK lesions, (p<0.0001), a complete clearance rate of 27.4%...

Want to see the full article?

• Purchase this article for only $3.00